Chardan Healthcare Acquisition 2 Corp. (CHAQ): Price and Financial Metrics
GET POWR RATINGS... FREE!
CHAQ Stock Price Chart Interactive Chart >
CHAQ Price/Volume Stats
|Current price||$10.00||52-week high||$11.37|
|Prev. close||$9.95||52-week low||$9.57|
|Day high||$10.01||Avg. volume||53,299|
|50-day MA||$10.08||Dividend yield||N/A|
|200-day MA||$10.08||Market Cap||107.78M|
Chardan Healthcare Acquisition 2 Corp. (CHAQ) Company Bio
Chardan Healthcare Acquisition 2 Corp. intends to acquire assets and businesses through a merger, share exchange, stock purchase, recapitalization, reorganization, or other similar business combination. The company was founded in 2018 and is based in New York, New York.
CHAQ Latest News Stream
|Loading, please wait...|
CHAQ Latest Social Stream
View Full CHAQ Social Stream
Latest CHAQ News From Around the Web
Below are the latest news stories about Chardan Healthcare Acquisition 2 Corp that investors may wish to consider to help them evaluate CHAQ as an investment opportunity.
Lifshitz Law Firm, P.C. Announces Investigation of ARPO, CNBKA, CHAQ, DSSI, INSW, FORE, FTIV, ONB, FMBI, and GRA
Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Chardan Healthcare Acquisition 2 Corp. Merger
WILMINGTON, Del., June 07, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Chardan Healthcare Acquisition 2 Corp. (“Chardan Healthcare”) (NYSE: CHAQ) regarding possible breaches of fiduciary duties and other violations of law related to Chardan Healthcare’s agreement to merge with Renovacor, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-chardan-healthcare-acquisition-2-corp. You may also contact Seth D. Rigrodsk
Former chief medical officer of MyoKardia to lead clinical development at RenovacorPHILADELPHIA and BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system (“CNS”) diseases resulting from BAG3 gene variants, today announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor. Dr. Semigran brings cons
Here's What Chardan Healthcare Acquisition 2 Corp.'s (NYSEMKT:CHAQ) Shareholder Ownership Structure Looks Like
The big shareholder groups in Chardan Healthcare Acquisition 2 Corp. ( NYSEMKT:CHAQ ) have power over the company...
CHAQ Price Returns